Akebia Therapeutics Inc. [AKBA] stock is trading at $1.26, down -0.79%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKBA shares have gain 34.66% over the last week, with a monthly amount glided 13.51%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on August 28, 2023, and kept the price target unchanged to $3.75. On May 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on March 31, 2022. Needham downgraded its rating to a Hold. Mizuho downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $10 to $2.
Akebia Therapeutics Inc. [AKBA] stock has fluctuated between $0.78 and $2.48 over the past year. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc. [NASDAQ: AKBA] shares were valued at $1.26 at the most recent close of the market. An investor can expect a potential return of 415.87% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
Akebia Therapeutics Inc. [NASDAQ:AKBA] reported sales of 187.22M for the trailing twelve months, which represents a drop of -18.74%. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at -0.19%, Pretax Profit Margin comes in at -0.23%, and Net Profit Margin reading is -0.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is 1.39 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-3.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1733 points at the first support level, and at 1.0867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3433, and for the 2nd resistance point, it is at 1.4267.
Ratios To Look Out For
For context, Akebia Therapeutics Inc.’s Current Ratio is 1.70. As well, the Quick Ratio is 1.31, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 1.41.
Transactions by insiders
Recent insider trading involved Dahan Michel, SVP, Chief Operating Officer, that happened on May 13 ’24 when 34840.0 shares were sold. SVP, Chief Legal Officer, Hadas Nicole R. completed a deal on May 13 ’24 to sell 12016.0 shares. Meanwhile, CEO and President Butler John P. sold 46570.0 shares on Feb 29 ’24.
